U.S. pharma giant copyright scrapped two experimental weight loss tablets previous calendar year—a at the time-day-to-day tablet, lotiglipron, due to elevated liver enzymes in addition to a twice-day by day pill, danuglipron, due to potent Uncomfortable side effects—but CEO Albert Bourla has claimed the company is determined to “Participate i